Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary

PASADENA, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Jacobs Engineering Group Inc. (NYSE: JEC) announced today that it received a contract from Gedeon Richter (BSE: GDRB) to provide engineering, procurement, and construction management services and validation assistance for a grassroots, multi-purpose biotechnology research & development and manufacturing facility in Debrecen, Hungary.

Officials did not disclose contract details but noted they would execute the work from their office in Milan, Italy.

Gedeon Richter, headquartered in Budapest, Hungary, is one of the largest multinational pharmaceutical companies in Central Eastern Europe and the Commonwealth of Independent States. It has a growing presence through commercial subsidiaries in key European Union countries, Asia, and the United States.

In making the announcement, Jacobs Group Vice President Robert Matha said "We are eager to help Gedeon Richter with this important project, which strengthens its commitment to biotechnology. In supporting the company's strategic goal of establishing a strong biopharma line, we also help Gedeon Richter to expand its worldwide portfolio of high value products."

Jacobs, with over 56,000 employees and revenues exceeding $10.0 billion, provides technical, professional, and construction services globally.

Any statements made in this release that are not based on historical fact are forward-looking statements. Although such statements are based on management's current estimates and expectations, and currently available competitive, financial, and economic data, forward-looking statements are inherently uncertain. We, therefore, caution the reader that there are a variety of factors that could cause business conditions and results to differ materially from what is contained in our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2007 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We also caution the readers of this release that we do not undertake to update any forward-looking statements made herein.

For additional information contact:

Michelle Jones

626.578.6968

SOURCE Jacobs Engineering Group Inc.